PRINCEPS DIVISION

Divalnus XR® Divalproex Sodium Extended-Release Tablets

DIVALNUS XR® is an extended-release formulation containing divalproex sodium, available in 250 mg, 500 mg and 750 mg tablet strengths. Explore its product composition, formulation details and important prescribing information for healthcare professionals.
DIVALNUS XR Divalproex Sodium Extended-Release Tablets by Seginus Pharma

PRODUCT OVERVIEW

About Divalnus XR®

DIVALNUS XR® contains divalproex sodium in an extended-release tablet formulation. It is available in three strengths: 250 mg, 500 mg and 750 mg, as specified for this product range.

The extended-release formulation is designed to release the medicine over an extended period. Its formulation characteristics distinguish it from immediate-release and other delayed-release preparations.

This page provides an overview of the QEGINUS® product range, its available strengths and important safety information for healthcare professionals. Treatment decisions, dosage and monitoring must be determined by a qualified prescriber.

Medical neuroscience illustration representing neurological care

Composition & Therapeutic Profile

DIVALNUS XR® features an extended-release divalproex sodium formulation, available in three tablet strengths. Explore its composition, therapeutic classification and product profile, with an emphasis on responsible use and approved prescribing information.

Pharmaceutical formulation ingredients icon

Composition

250 mg | 500 mg | 750 mg

Topical analgesic formulation icon

Therapeutic Class

A medicine belonging to the antiepileptic and anticonvulsant therapeutic class.

Localized pain management icon

Therapeutic Focus

Product information for approved therapeutic indications, subject to the applicable prescribing information.

How divalnus XR® Works

Divalproex sodium is an anticonvulsant medicine that is converted to valproate in the body. Its pharmacological activity involves multiple mechanisms in the central nervous system, including effects on gamma-aminobutyric acid (GABA), an important neurotransmitter involved in regulating neuronal activity.

Valproate influences neuronal signalling and excitability. Its precise mechanism of action is not fully established and may involve several pathways.

DIVALNUS XR® uses an extended-release tablet formulation designed to release the medicine over an extended period. It should be administered strictly according to the approved product instructions.

Key points

Medical illustration representing neuronal signalling and brain activity

Clinical & Therapeutic Areas

DIVALNUS XR® contains divalproex sodium, an anticonvulsant medicine used in the management of certain neurological and psychiatric conditions. Its therapeutic applications depend on the approved indications, individual patient requirements and applicable prescribing information.

Medical illustration representing liver, pancreatic and pregnancy-related safety considerations
Seizure Management

Seizure Management

Divalproex may be prescribed for specified seizure disorders, according to approved product indications.

Bipolar Disorder

Bipolar Disorder

Divalproex has an established role in certain aspects of bipolar disorder management, where approved and clinically appropriate.

Migraine Prevention

Migraine Prevention

Divalproex may be used for migraine prevention in specific approved circumstances. It is not intended for treating an acute migraine attack.

Frequently Asked Questions

DIVALNUS XR® is an extended-release divalproex sodium tablet formulation intended for use according to its approved prescribing information.

The product range is specified as 250 mg, 500 mg and 750 mg strengths. Please confirm these strengths against the approved product artwork and pack information before publication.

Divalproex sodium is used for certain neurological and psychiatric conditions. The approved indications for DIVALNUS XR® must be confirmed from its current approved Indian prescribing information.

Divalproex sodium carries important risks, including serious liver and pancreatic problems and significant pregnancy-related risks. Appropriate medical assessment and monitoring are essential.

No. Treatment should not be started, stopped or adjusted without consulting the prescribing healthcare professional.

Discover Our Specialty Pharmaceutical Portfolio

Explore the MERGA and PRINCEPS divisions of Seginus Pharma and discover our portfolio of pharmaceutical products across key therapeutic areas.